Understanding Glaucoma Risk and Tailored Treatments
Understanding glaucoma risk and assessment of precision therapies: A study of mitochondria and oxidative stress in human trabecular meshwork
This work explores why some people develop glaucoma earlier or more severely, focusing on how cell damage in the eye contributes to this common cause of blindness.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11131251 on NIH RePORTER |
What this research studies
Glaucoma is a leading cause of blindness, and we know that some individuals develop it earlier or more severely due to various factors. This project aims to understand why certain cells in the eye, called trabecular meshwork cells, become damaged, leading to increased eye pressure. We believe this damage is linked to differences in how these cells process oxygen, which can vary based on a person's genetic makeup. By studying eye fluid from patients with severe glaucoma and comparing eye cells from healthy and affected donors, we hope to uncover the root causes of this oxidative damage. This deeper understanding is crucial for developing more targeted and effective treatments.
Who could benefit from this research
Good fit: Patients with glaucoma, particularly those with severe forms, or individuals at higher risk for developing the condition, are the ultimate beneficiaries of this foundational research.
Not a fit: Patients whose glaucoma is not primarily driven by oxidative stress or mitochondrial issues may not directly benefit from treatments specifically developed through this research.
Why it matters
Potential benefit: If successful, this work could lead to new, more precise treatments for glaucoma by targeting the specific causes of cell damage in the eye.
How similar studies have performed: While previous studies have strongly linked oxidative damage to glaucoma, this project explores the specific causes of this damage and its connection to oxygen metabolism in a novel way.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Siegfried, Carla J — Washington University
- Study coordinator: Siegfried, Carla J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.